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Introduction
B-cell chronic lymphoproliferative disorders (B-CLPD) usual-
ly show a monoclonal expansion of a (single) mature-appear-
ing aberrant B-cell clone.1-4 However, patients diagnosed with
composite lymphomas and other B-cell chronic lymphocytic
leukemias – e.g. chronic lymphocytic leukemia (CLL) – have
been reported in the literature for decades, particularly among
immunocompromised subjects.5-7 Although early reports con-
sidered this phenomenon as a rare event, it might have been
underestimated because its detection requires sophisticated
multidisciplinary approaches encompassing combined
histopathology, cytomorphology, immunophenotypic and
cytogenetic techniques and/or molecular analyses of purified
cell populations.8 In fact, B-cell neoplasms consisting of two
phenotypically distinct populations of clonally unrelated B-
lymphocytes coexisting in the same patient (detected either
simultaneously or at different time points during follow-up)
have been reported in the literature,9,10 with an estimated over-
all frequency among B-CLPD patients of around 5%.11
Recently, it has also been shown that up to 20% of cases of
population-based non-CLL and CLL-like low count monoclon-
al B-cell lymphocytosis (MBLlo) may also carry two different
unrelated B-cell clones.12-14 In addition, data from a small series
suggest that the frequency of multiclonality could be particu-
larly high among CLL-like MBL cases in relatives of patients
with CLL, (4/6 cases analyzed).12 Altogether, these results sup-
port the existence of multiclonality in a significant proportion
of both MBL cases and B-CLPD patients. 
Multiclonal MBL and B-CLPD cases may consist of expan-
sions of two or more B-cell clones potentially associated with
chronic antigen-driven immune responses.15-17 In fact, this is
particularly frequent in the earlier stages of MBLlo, which
would further support the potential reactive nature of MBL
among individuals with normal lymphocyte counts, prior to
the stepwise acquisition of genetic alterations and progression
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Chronic antigen-stimulation has been recurrently involved in the earlier stages of monoclonal B-cell lymphocyto-
sis, chronic lymphocytic leukemia and other B-cell chronic lymphoproliferative disorders. The expansion of two
or more B-cell clones has frequently been reported in individuals with these conditions; potentially, such coexisting
clones have a greater probability of interaction with common immunological determinants. Here, we analyzed the
B-cell receptor repertoire and molecular profile, as well as the phenotypic, cytogenetic and hematologic features,
of 228 chronic lymphocytic leukemia-like and non-chronic lymphocytic leukemia-like clones comparing multi-
clonal (n=85 clones from 41 cases) versus monoclonal (n=143 clones) monoclonal B-cell lymphocytosis, chronic
lymphocytic leukemia and other B-cell chronic lymphoproliferative disorders. The B-cell receptor of B-cell clones
from multiclonal cases showed a slightly higher degree of HCDR3 homology than B-cell clones from mono clonal
cases, in association with unique hematologic (e.g. lower B-lymphocyte counts) and cytogenetic (e.g. lower fre-
quency of cytogenetically altered clones) features usually related to earlier stages of the disease. Moreover, a sub-
group of coexisting B-cell clones from individual multiclonal cases which were found to be phylogenetically relat-
ed showed unique molecular and cytogenetic features: they more frequently shared IGHV3 gene usage, shorter
HCDR3 sequences with a greater proportion of IGHV mutations and del(13q14.3), than other unrelated B-cell
clones. These results would support the antigen-driven nature of such multiclonal B-cell expansions, with potential
involvement of multiple antigens/epitopes.
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ABSTRACT
to clinical MBL (MBLhi) and CLL.13,14,18,19 If this hypothesis
holds true, specific antigenic determinants could potentially
be more frequently shared between the coexisting B-cell
clones of multiclonal cases than between the expanded B
cells in different monoclonal MBL and B-CLPD patients,
due to a higher probability of interaction with common
immunological determinants. This might even be true
when the coexisting clones display clearly distinct
immunophenotypic and cytogenetic, as well as clinical, fea-
tures.20-22
In order to test this hypothesis, in the present study we
compared the B-cell receptor (BCR) repertoire and molecu-
lar profile, as well as the phenotypic, cytogenetic and hema-
tologic features of CLL-like and non-CLL-like clones
(n=228) from multiclonal (n=41 cases) versus monoclonal
cases [n=143, including both CLL and CLL-like MBL
(n=128), as well as cases of B-CLPD other than CLL and
non-CLL-like MBL (n=15)]. 
Methods
Patients and samples
A total of 184 subjects with one (n=143 monoclonal cases) or
two or more (n=41 multiclonal cases) CLL/non-CLL B-CLPD
(n=140) and/or CLL-like/non-CLL-like MBL (n=88) B-cell clones,
as defined by the World Health Organization 2008 criteria,23 were
included. Binet stage24 of CLL subjects was retrospectively col-
lected. 
From the 41 multiclonal cases, two (5%) corresponded to
healthy individuals with CLL-like MBLlo, eight (19.5%) were
CLL-like MBLhi cases, 23 (56%) had CLL and eight (19.5%) had
B-CLPD other than CLL; four of these latter cases showed coex-
istence of either one or two CLL-like MBL B-cell population(s). In
3/41 multiclonal cases, three coexisting B-cell populations were
detected. From the 143 monoclonal cases, 13 (9%) corresponded
to healthy adults with CLL-like MBLlo, 26 (18%) had CLL-like
MBLhi, 89 (62%) had CLL, two (1%) had non-CLL-like MBLlo,
two (1%) were non-CLL-like MBLhi cases and 11 (8%) had other
B-CLPD. The precise criteria used for the classification of MBLlo
and MBLhi are detailed in the Online Supplementary Methods. The
age/gender distribution for each diagnostic group is detailed in
Online Supplementary Table S1.
Peripheral blood samples were obtained from each subject
after written informed consent had been given, and the study
was approved by the local ethics committees of the University
Hospital of Salamanca and the Blood and Transplantation Center
of Coimbra/Portuguese Institute of Blood and Transplantation, in
accordance with the Helsinki Declaration of 1975, as revised in
2008. 
Immunophenotypic analyses
Immunophenotypic studies to screen for the presence and full
characterization of clonal B-cell populations were performed by
high-sensitive multiparameter flow cytometry on erythrocyte-
lysed peripheral blood samples, according to previously
described procedures18,25-29 which are also detailed in the Online
Supplementary Methods. All cases showed a clonal (imbalanced
SmIgκ:SmIgλ ratio of >3:1 or <1:3) and/or aberrant CD5+ B-cell
population.
Cytogenetic and molecular studies
Cytogenetic analyses were performed by multicolor inter-
phase fluorescence in situ hybridization on slides containing
FACS-purified and fixed aberrant B cells, as previously described
in detail.18,30 In parallel, patterns of rearrangement of the
immunoglobulin heavy chain variable region genes (IGHV) and
immunoglobulin κ (IGKV) and λ (IGLV) light chain genes were
analyzed for each FACS-purified B-cell clone18,31-32 (see the Online
Supplementary Methods section for detailed descriptions). To
investigate the level of phylogenetic relationship among IGHV
amino acid sequences, a sequence distance tree was built using
the neighbor-joining method implemented in the freely available
Molecular Evolutionary Genetic Analysis (MEGA) software.33
Two different, coexisting BCR were considered as being phylo-
genetically related when their IGHV amino acid sequences, going
from framework region 1 to HCDR3 (both regions included),
showed an identity ≥ 60%. This “identity” threshold was based
on previously published concepts about the phylogeny of human
IGHV genes based on their amino acid sequences33, and on the
minimum identity percentage observed in colocalized sub-
branches (presumably with the highest evolutionary relation-
ship33) of the sequence distance tree built in this study (see the
Online Supplementary Methods section for more detailed descrip-
tions). HCDR3-alignments were carried out for each multiclonal
case whose coexisting B-cell clones showed HCDR3 regions with
identical lengths or lengths differing by one amino acid using the
bioinformatic tools available at the web services of the European
Bioinformatics Institute (EMBL-EBI Cambridge, UK). Through
the EMBL-EBI tools, the identical amino acids or those with anal-
ogous side-chain polarity per paired intra-case HCDR3-align-
ment were highlighted (see the Online Supplementary Methods sec-
tion for more detailed descriptions).
Statistical methods
For all statistical analyses the SPSS software program (SPSS
20.0, IBM SPSS Statistics, IBM, Armonk, NY, USA) was used. 
Results
Distribution and immunophenotypic features 
of B-cell clones 
A total of 228 B-cell clones were identified. These corre-
sponded to 143 B-cell clones (89 CLL, 11 non-CLL, 39
CLL-like MBL and 4 non-CLL-like MBL clones) from
mono clonal cases and 85 B-cell clones (26 CLL, 14 non-
CLL, 40 CLL-like MBL and 5 non-CLL-like MBL clones)
from multiclonal cases (Online Supplementary Table S2).
The complete immunophenotypic and cytogenetic fea-
tures of the individual clones of multiclonal cases are sum-
marized in Online Supplementary Table S3.
In 26/41 multiclonal cases, all coexisting B-cell clones
showed a CLL-like phenotype, while in 11 of the remain-
ing 15 cases, at least one CLL-like B-cell population coex-
isting with another non-CLL aberrant B-cell population
was identified. In the remaining four cases, two distinct
non-CLL-like B-cell clones were found (Online
Supplementary Table S3). The distribution of all CLL/non-
CLL and CLL-like MBL/non-CLL-like MBL clones ana-
lyzed (from all monoclonal and multiclonal cases consid-
ered together) in the distinct diagnostic categories was as
follows: 27 B-cell clones corresponded to CLL-like MBLlo,
52 to CLL-like MBLhi, 115 to CLL, 5 to non-CLL-like MBLlo,
4 to non-CLL-like MBLhi and 25 to non-CLL B-CLPD
(Online Supplementary Table S2). The precise diagnoses of
the B-cell clones from patients with B-CLPD other than
CLL are specified in the footnote to Online Supplementary
Table S2.
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Overall size and B-cell receptor features of B-cell
clones from multiclonal versus monoclonal cases of
monoclonal B-cell lymphocytosis, chronic lymphocytic
leukemia, and other B-cell chronic lymphoproliferative
diseases 
The relative and absolute median number of peripheral
blood clonal B cells was significantly lower in multiclonal
than in monoclonal cases (13% versus 45% and 2,692
cells/mL versus 9,115 cells/mL, respectively; P=0.001). Of
note, the absolute median numbers of CLL-like MBLhi
and CLL B-cell clones were also significantly lower in
multiclonal than in monoclonal cases (1,254 versus 2,464
cells/mL and 9,113 versus 18,600 cells/mL, respectively;
P=0.004 and P=0.02) (Online Supplementary Figure S1). In
contrast, the absolute median number of peripheral
blood CLL-like MBLlo B-cell clones was significantly
higher in multiclonal than in monoclonal cases (79 versus
1 cells/ mL; P=0.002). No significant differences were
found in the clone size between non-CLL-like and non-
CLL B-cell clones in multiclonal versus monoclonal cases
(Online Supplementary Figure S1). In addition, the frequen-
cy of CLL-like MBL B-cell clones was significantly higher
in multiclonal than in mono clonal cases (47% versus
27%, respectively; P=0.002), whereas the frequency of
CLL B-cell clones was higher in monoclonal versus multi-
clonal subjects (62% versus 31%, respectively; P=0.001).
CLL B-cell clones from multiclonal and monoclonal CLL
patients showed a similar distribution in Binet stage A
versus Binet stages B/C (P>0.05). Of note, non-CLL B-cell
clones were present at higher frequencies in multiclonal
versus monoclonal cases (17% versus 8%, respectively;
P=0.04) (Table 1).
Regarding BCR features, a similar distribution of IGHV-
mutated and IGHV-unmutated B-cell clones was found in
multiclonal versus monoclonal cases: 51/85 (60%) versus
84/139 (60%) and 34/85 (40%) versus 55/139 (40%),
respectively (Table 1). Despite this, the percentage of
alignment of IGHV amino acid sequences among B-cell
clones from multiclonal cases (n=3,560 two by two com-
parisons of clonal IGHV amino acid sequence) was slight-
ly higher than that obtained among B-cell clones from
monoclonal cases (n=8,891 comparisons): median of 52%
versus 50%, respectively (P=0.001; Table 1). 
Cytogenetic features of B-cell clones from multiclonal
versus monoclonal cases of monoclonal B-cell 
lymphocytosis and  B-cell chronic 
lymphoproliferative diseases 
The frequency of CLL-like MBL and CLL clones from
multiclonal cases that showed cytogenetic alterations was
significantly lower than that found among CLL-like MBL
and CLL clones from monoclonal cases: 27/66 (41%) versus
77/128 (60%), respectively (P=0.02). Likewise, the propor-
tion of CLL-like B-cell clones showing coexistence of two
or more cytogenetic alterations was also significantly
lower in multiclonal than in monoclonal cases: 8/66 (12%)
versus 32/128 (25%; P=0.047). This was specially true
among B-cell clones from CLL patients: 2/26 (8%) versus
29/89 (33%), respectively (P=0.03; Table 2).
Regarding each specific cytogenetic alteration, only a
decreased frequency of CLL-like B-cell clones with
del(13q14) involving the RB1 gene and a lower percentage
of del(13q14)+ cells was found in multiclonal versus mono-
clonal cases: the frequency of del(13q14)+ clones was 5%
versus 15% with a median of del(13q14)+ cells of 55% ver-
sus 86%, respectively (P=0.01; Table 2). Of note, these dif-
ferences were mostly due to the lower frequency of B-cell
clones with del(13q14) (4% versus 19%, P=0.01) found
among CLL clones from multiclonal versus monoclonal
cases (Table 2). 
Multiclonal B-CLPD: molecular and cytogenetic features 
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Table 1. Peripheral blood B-cell counts and BCR features of multiclonal vs. monoclonal B-cell clones from cases of B-cell chronic lymphoprolif-
erative disorders and monoclonal B-cell lymphocytosis.
Multiclonal B-cells Monoclonal B-cells Total
n=85 clones n=143 clones n=228 clones
N. of  PB clonal B cells(x106/L)* 2,692 (0.6-156,168)a 9,115 (0.1-369,288) 5,530 (0.1-369,288)
% of PB clonal B cells from WBC* 13% (0.1%-89%)a 45% (0.002%-97%) 35% (0.001%-97%)
CLL-like MBLlo B-cell clones 14/85 (16%) 13/143 (9%) 27/228 (12%)
CLL-like MBLhi B-cell clones 26/85 (31%)a 26/143 (18%) 52/228 (38%)
CLL B-cell clones 26/85 (31%)a 89/143 (62%) 113/228 (50%)
CLL-stage A clones 12/20 (60%) 53/89 (60%) 65/109 (60%)
CLL-stage B/C clones 8/20 (40%) 36/89 (40%) 44/109 (40%)
Non-CLL-like MBL B-cell clones 5/85 (6%) 4/143 (3%) 9/228 (4%)
Non-CLL B-cell clones 14/85 (17%)a 11/143 (8%) 25/228 (11%)
IGHVmutated CLL-like  B-cell clones 40/66 (61%) 76/128 (59%) 116/194 (60%)
IGHVmutated non-CLL-like  B-cell clones 11/19 (58%) 8/15 (53%) 19/34 (56%)
%  alignment of IGHV aa sequences  between 51% (38%-79%) NA 51% (38%-79%)
coexisting B-cell clones*
% alignment of IGHV aa sequences between each 52% (31%-100%)a 50% (29%-100%) 51% (29%-100%)
B-cell clone and the other clones*
Results expressed as number of B-cell clones and percentage between brackets or as *median value (range). PB: peripheral blood; WBC: white blood cells; CLL: chronic lymphocytic
leukemia/small lymphocytic lymphoma; MBLlo: low count monoclonal B-cell lymphocytosis; IGHV: immunoglobulin heavy chain variable region genes; MBLhi: clinical monoclonal
B-cell lymphocytosis; aa: amino acids. NA: not applicable. aStatistically significant differences (P<0.05) found between clones from multiclonal vs. monoclonal cases. Information
about the parameters included in this table is displayed separately for CLL-like vs. non-CLL-like clones in Online Supplementary Table S7.
No statistically significant differences were observed in
the cytogenetic patterns of non-CLL B-cell clones from
multiclonal versus monoclonal cases, which is probably
due to the relatively low number of non-CLL clones
included in the study; the precise cytogenetic alterations
found in non-CLL/non-CLL-like MBL cases are shown in
Online Supplementary Tables S3 and S4. In turn, the overall
cytogenetic features of non-CLL like B-cell clones from
multiclonal subjects (n=19; 3 non-CLL MBLlo, 2 non-CLL
MBLhi, 14 non-CLL B-cell clones) versus monoclonal sub-
jects (n=15; 2 non-CLL MBLlo, 2 non-CLL MBLhi, 11 non-
CLL B-cell clones) were similar, as regards both the fre-
quency of cytogenetically altered clones (6/19, 32% and
6/15, 40%) and the percentage of cases with two or more
genetic alterations: 2/19 (11%) versus 2/15 (13%) (Online
Supplementary Tables S3 and S4).
Molecular characteristics of the B-cell receptors 
of B-cell clones from multiclonal versus monoclonal
cases of monoclonal B-cell lymphocytosis and B-cell
chronic lymphoproliferative diseases
The molecular profile of the BCR of CLL-like MBLlo,
MBLhi and CLL B-cell clones and of B-cell clones other
than CLL from multiclonal versus monoclonal cases was
very similar (Table 3 and Online Supplementary Table S5).
No statistically significant differences in multiclonal versus
monoclonal VH gene usage were found for most groups.
Despite this general behavior, CLL-like MBLhi B-cell
clones from multiclonal cases less frequently showed
usage of the DH1, DH4 and DH7 gene families than B-cell
clones from monoclonal cases; in addition, JH6 genes
were also less frequently used by CLL B-cell clones from
multiclonal versus monoclonal cases (Table 3). Overall, 33
functional IGHV gene rearrangements were identified
from which 12 (V4-34, V3-23, V3-48, V3-30, V1-69, V3-
21, V4-39, V3-33, V3-11, V3-53, V1-2, V3-7) were highly
represented among the B-cell clones (≥5% of all B-cell
clones corresponding to ≥4 and ≥5 B-cell clones sharing
the same IGHV gene in multiclonal and monoclonal
cases, respectively) (Figure 1A). Interestingly, 11 of these
IGHV genes were found at similar frequencies within the
clones of multiclonal versus monoclonal cases, while the
V3-33 gene was typically associated with multiclonal
cases (6% versus 1%, P=0.03). Regarding IGHD genes, no
significant differences were observed between B-cell
clones from multiclonal and monoclonal cases, the D3-3,
D5-12, D3-10, D6-19, D2-15, and D2-2 genes being the
most frequently used and shared by both groups of B-cell
clones (Figure 1B). Among IGHJ genes, significant differ-
ences were only observed for the JH6 gene, which was
more frequently used in monoclonal cases (40% versus
26%; P=0.03) (Figure 1C).
Except for slightly longer LCDR3 sequences of the
IGKV and IGLV genes found among B-cell clones from
multiclonal versus monoclonal cases, especially among
CLL-like MBLhi clones (Table 3), no other significant differ-
Table 2. Cytogenetic features of CLL-like MBLlo, MBLhi and CLL B-cell clones from monoclonal vs. multiclonal cases.
Cytogenetic alterations MBLlo clones MBLhi clones CLL clones Total
Multiclonal Monoclonal Multiclonal Monoclonal Multiclonal Monoclonal Multiclonal Monoclonal
n=14 n=13 n=26 n=26 n=26 n=89 n=66 n=128
N. of cytogenetically altered clones 2/14 (14%) 6/13 (46%) 13/26 (50%) 13/26 (50%) 12/26 (46%) 58/89 (65%) 27/66 (41%)b 77/128 (60%)
N. of clones with ≥2 alterations 1/14 (7%) 1/13 (8%) 5/26 (19%) 2/26 (8%) 2/26 (8%)a 29/89 (33%) 8/66 (12%)b 32/128 (25%)
Type of cytogenetic changes
N. of del(13q)+ clones (%) 2/14  (14%) 5/13 (38%) 7/26 (27%) 8/26  (31%) 8/26 (31%) 36/89 (40%) 17/66 (26%) 49/128 (38%)
% del(13q)+ cells * 46% (19%-73%) 86% (22%-96%) 74% (15%-98%) 38% (21%-99%) 93% (30%-96%) 80% (47%-99%) 84% (10%-98%) 79% (18%-99%)
N. of del(13q14.3)+ clones (%) 2/14  (7%) 4/13 (31%) 7/26 (27%) 8/26 (31%) 8/26 (31%) 35/89 (39%) 17/66 (26%) 47/128 (37%)
% del(13q14.3)+ cells * (19%-73%) 78% (22%-96%) 65% (15%-98%) 38% (21%-99%) 81% (30%-96%) 73% (5%-99%) 80% (15%-98%) 71% (5%-99%)
N. of del(13q14)+ clones (%) 0/14 (0%) 1/12 (8%) 2/26 (8%) 1/26 (4%) 1/26 (4%)a 17/89 (19%) 3/66 (5%)b 19/127 (15%)
% del(13q14)+ cells * - 86% (-) 57% (15%-98%) 96% (-) 95% (-) 79% (47%-99%) 55% (10%-98%)b 86% (47%-99%)
N. of trisomy 12+ clones (%) 0/14 (0%) 1/13 (8%) 6/26 (23%) 5/26 (19%) 2/26 (8%) 17/89 (19%) 8/66 (12%) 23/128 (18%)
% trisomy 12+ cells * - 59% (-) 87% (19%-95%) 84% (80%-93%) 84% (75%-93%) 76% (33%-97%) 87% (41%-95%) 80% (33%-97%)
N. of t(14q32)+ clones (%) 0/12 (0%) 0/10 (0%) 2/26 (8%) 0/26 (0%) 1/26 (4%) 10/89 (11%) 3/64 (5%) 10/125 (8%)
% t(14q32)+ cells * - - 42% (31%-52%) - 98% (-) 82% (18%-94%) 72% (28%-98%) 59% (18%-94%)
N. of del(11q)+ clones (%) 0/12 (0%) 0/11 (0%) 1/26 (4%) 1/26 (4%) 1/26 (4%) 7/89 (8%) 2/64 (3%) 8/126 (6%)
% del(11q)+ cells * - - 93% (-) 20% (-) 91% (-) 57% (21%-98%) 92% (91%-93%) 57% (20%-98%)
N. of del(11q22.3)+ clones (%) 0/12 (0%) 0/11 (0%) 1/26 (4%) 1/26 (4%) 1/26 (4%) 6/89 (7%) 2/64 (3%) 7/126 (6%)
% del(11q22.3)+ cells * - - 93% (-) 20% (-) 91% (-) 70% (24%-98%) 92% (91%-93%) 68% (20%-98%)
N. of del(11q23)+ clones (%) 0/12 (0%) 0/11 (0%) 0/26 (0%) 0/26 (0%) 0/26 (0%) 3/89 (3%) 0/64 (0%) 3/126 (2%)
% del(11q23)+ cells * - - - - - 32% (21%-64%) - 40% (24%-64%)
N. of del(17p13.1)+ clones (%) 0/13 (0%) 0/12 (0%) 0/26 (0%) 0/26 (0%) 0/26 (0%) 5/89 (6%) 0/65 (0%) 5/127 (4%)
% del(17p13.1)+ cells * - - - - - 44% (33%-88%) - 44% (33%-88%)
Results expressed as number of clones with cytogenetic changes from all clones in the corresponding group (percentage) or as *median values of altered cells/clone (range). In seven clones (1 multiclonal
MBLlo, 3 monoclonal and 3 multiclonal CLL clones) biallelic del(13q14.3) was detected, and polysomy was found  in one multiclonal CLL clone. Statistically significant differences  (shown in bold) were
found between multiclonal vs. monoclonal B-cell clone groups for aCLL clones (P=0.01) and ball (total) clones (P=0.01). CLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; MBL: monoclonal
B-cell lymphocytosis.
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ences were found in the molecular characteristics of the
immunoglobulin light chain genes, either among CLL-like
or non-CLL like B-cell clones from multiclonal versusmon-
oclonal cases (Table 3 and Online Supplementary Table S5).
Regarding IGKV and IGLV genes, only the VK1-33 gene
was associated with multiclonal cases (6% versus 0%;
P=0.02) (Figure 1D)
Molecular features of phylogenetically related B-cell
receptors of B-cell clones from multiclonal cases 
Thirty-two of the 85 B-cell clones from individual mul-
ticlonal cases were phylogenetically closely related and
had exactly the same IGHV family (IGHV3 in 28 B-cell
clones and IGHV4 in 4 B-cell clones) (Figure 2). Of note,
this subgroup of B-cell clones frequently showed IGHV3
gene usage (28/85, 33%) and they displayed shorter
HCDR3 sequences than other (multiclonal and mono-
clonal) B-cell clones: 13 (6-25) versus 17(9-26) and 16 (8-
32) amino acids (P=0.001 and P=0.004, respectively). In
addition, they also showed a higher frequency of
del(13q14.3) compared to B-cell clones from multiclonal
cases expressing phylogenetically unrelated IGHV fami-
lies (41% versus 17%, respectively; P=0.05). Moreover, a
slightly higher frequency of multiclonal cases whose
coexisting clones were cytogenetically altered was found
among phylogenetically closely related clones versus phy-
logenetically unrelated clones from multiclonal cases
(53% versus 34%, respectively; P=0.06). Interestingly, a
trend towards an increased percentage of IGHV-mutated
B-cell clones among phylogenetically related B-cell
clones from multiclonal cases compared to other B-cell
clones from multiclonal cases was also found (70% versus
54%, respectively; P=0.1). Interestingly, most of the coex-
isting phylogenetically related clones had a CLL-like phe-
Table 3. Molecular characteristics of the B-cell receptor (BCR) of chronic lymphocytic leukemia (CLL)-like monoclonal B-cell lymphocytosis (MBL)lo, MBLhi and CLL B-
cell clones from monoclonal versus multiclonal cases. 
MBLlo clones MBLhi clones CLL clones Total
Multiclonal Monoclonal Multiclonal Monoclonal Multiclonal Monoclonal Multiclonal Monoclonal 
n= 14 n= 13 n= 26 n= 25 n= 26 n= 87 n= 66 n= 126
HCDR3 length* (N. of aa) 15 (6-22) 13 (11-20) 16 (8-23) 17 (9-26) 17 (11-26) 18 (8-32) 17 (6-26) 17 (8-32)
VH families
VH1 2/14 (14%) 2/13 (15%) 3/26 (12%) 4/25 (16%) 4/26 (15%) 25/87 (29%) 9/66 (14%) 31/125 (25%)
VH3 9/14 (65%) 9/13 (69%) 15/26 (58%) 16/25 (64%) 11/26 (42%) 36/87 (41%) 35/66 (53%) 61/125 (49%)
VH4 2/14 (14%) 2/13 (15%) 6/26 (23%) 3/25 (12%) 9/26 (35%) 23/87 (27%) 17/66 (26%) 28/125 (22%)
VH2, VH5, VH6 1/14 (7%) 0/13 (0%) 2/26 (8%) 2/25 (8%) 2/26 (8%) 3/87 (3%) 5/66 (7%) 5/125 (4%)
DH families
DH1, DH4, DH7 3/14 (21%) 2/13 (15%) 1/26 (4%)a 6/24 (25%) 6/26 (23%) 11/86 (13%) 10/66 (15%) 19/123 (16%)
DH2 2/14 (14%) 3/13 (23%) 5/26 (19%) 7/24 (29%) 4/26 (15%) 15/86 (17%) 11/66 (17%) 25/123 (20%)
DH3 3/14 (21%) 2/13 (15%) 9/26 (35%) 7/24 (29%) 13/26 (50%) 36/86 (42%) 25/66 (38%) 45/123 (37%)
DH5 2/14 (14%) 3/13 (23%) 6/26 (23%) 2/24 (8%) 3/26 (12%) 9/86 (11%) 11/66 (17%) 14/123 (11%)
DH6 4/14 (29%) 3/13 (23%) 5/26 (19%) 2/24 (8%) 0/26 (0%) 15/86 (17%) 9/66 (13%) 20/123 (16%)
JH genes
JH1, JH2, JH3, JH5 3/14 (21%) 2/13 (15%) 7/26 (27%) 7/24 (29%) 9/26 (35%) 14/86 (16%) 19/66 (29%) 23/123 (19%)
JH4 6/14 (43%) 7/13 (54%) 13/26 (50%) 8/24 (33%) 10/26 (38%) 34/86 (40%) 29/66 (44%) 49/123 (40%)
JH6 5/14 (36%) 4/13 (31%) 6/26 (23%) 9/24 (38%) 7/26 (27%)a 38/86 (44%) 18/66 (27%)a 51/123 (41%)
LCDR3 length* (N. of aa) 9 (8-13) 10 (8-10) 10 (8-12)a 9 (7-12) 10 (8-15) 9 (5-12) 10 (8-15)a 9 (5-12)
VK families
VK1 0/6 (0%) 1/4 (25%) 6/14 (43%) 3/12 (25%) 6/12 (50%) 23/48 (48%) 12/32 (38%) 27/64 (42%)
VK2, VK5, VK6 1/6 (17%) 0/4 (0%) 1/14 (7%) 3/12 (25%) 2/12 (17%) 8/48 (17%) 4/32 (13%) 11/64 (17%)
VK3, VK4 5/6 (83%) 3/4 (75%) 7/14 (50%) 6/12 (50%) 4/12 (33%) 17/48 (35%) 16/32 (50%) 26/64 (41%)
JK genes
JK1, JK3, JK5 3/6 (50%) 1/4 (25%) 5/14 (36%) 7/12 (58%) 5/12 (42%) 21/47 (45%) 13/32 (40%) 29/63 (46%)
JK2 2/6 (33%) 2/4 (50%) 8/14 (57%) 3/12 (25%) 4/12 (33%) 10/47 (21%) 14/32 (44%) 15/63 (24%)
JK4 1/6 (17%) 1/4 (25%) 1/14 (7%) 2/12 (17%) 3/12 (25%) 16/47 (34%) 5/32 (16%) 19/63 (30%)
V families
V 3 2/3 (67%) NA 1/7 (14%) 0/7 (0%) 2/7 (29%) 8/25 (32%) 5/17 (29%) 8/32 (25%)
Other 1/3 (33%) NA 6/7 (86%) 7/7 (100%) 5/7 (71%) 17/25 (68%) 12/17 (71%) 24/32 (75%)
J  genes
Jλ1 1/3 (33%) NA 0/7 (0%) 0/7 (0%) 4/7 (57%) 6/21 (71%) 5/17 (29%) 6/28 (21%)
Other 2/3 (67%) NA 7/7 (100%) 7/7 (100%) 3/7 (43%) 15/21 (29%) 12/17 (71%) 22/28 (79%)
IGHV mutational status
Mutated IGHV 9/14 (64%) 8/11 (73%) 17/26 (65%) 20/25 (80%) 14/26 (54%) 46/86 (54%) 40/66 (61%) 74/122 (61%)
Unmutated IGHV 5/14 (36%) 3/11 (27%) 9/26 (35%) 5/25 (20%) 12/26 (46%) 40/86 (47%) 26/66 (39%) 48/122 (39%)
Results expressed as number of B-cell clones from all clones in the corresponding group (percentage) or as *median (range). CLL: chronic lymphocytic leukemia/small lymphocytic lymphoma; MBL:
monoclonal B-cell lymphocytosis; BCR: B-cell receptor; HCDR3: heavy chain complementarity-determining region 3; LCDR3: light chain complementarity-determining region 3; aa: amino acid. NA: not
analyzed; astatistically significant differences found between groups of clones from multiclonal vs. monoclonal cases (P≤0.03) are shown in bold. 
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notype (10/16 cases, identified in Online Supplementary
Table S3 by the ¶ symbol), while in 4/16 multiclonal cases,
one CLL-like B- cell clone coexisted with one non-CLL B-
cell clone, (2 marginal zone lymphomas, 1 lymphoma of
mucosa-associated lymphoid tissue and 1 hairy cell
leukemia clones from cases 29, 32, 37 and 38, also identi-
fied in Online Supplementary Table S3 with the ¶ symbol).
In a minority of cases (2/16), the two coexisting phyloge-
netically related clones were both non-CLL-like, their
phenotype being consistent with follicular lymphoma
and lymphoma of mucosa-associated lymphoid tissue
(case 16¶ and case 34¶, respectively, in Online
Supplementary Table S3).
Homology of the HCDR3 region between B-cell clones
coexisting in multiclonal cases versus non-coexisting
(monoclonal) B-cell clones
The HCDR3 amino acid sequence from coexisting B-cell
clones had the same length or differed by just one amino
acid in 8/41 multiclonal cases analyzed (19%) (Table 4A).
The homology of all these case-paired HCDR3 regions was
calculated as the number of identical amino acids or amino
acids with an analogous side-chain polarity [(excluding the
anchor second-CYS104 (C_) and the J-TRP 118 (_W) amino
acid positions that delineate the HCDR3 region)] divided by
the corresponding HCDR3 length (Table 4A). It is worth
noting that the amino acid composition of HCDR3
sequences of the same length (±1 amino acid) that belonged
to the same or evolutionary, highly-related VH families (e.g.
VH3-48, VH3-21, VH3-11)33 (n=57) from monoclonal cases
(Online Supplementary Table S6) showed a tendency towards
a lower homology than that of multiclonal cases: median of
37% (range: 11% to 71%) versus 50% (range: 26% to 64%),
respectively; (P=0.1). Since stereotyped sequences are wide-
ly represented in CLL,34 we further analyzed the frequency
of stereotyped HCDR3 sequences in multiclonal cases
(Table 4B) versusmonoclonal cases (Table 4C). Interestingly,
the number of multiclonal cases showing the same or high-
ly similar stereotyped HCDR3 sequences was significantly
higher than that of monoclonal cases: 8/41 (19%) versus
11/143 (8%), respectively (P=0.001). Furthermore, the
amino acid composition of HCDR3 sequences from mono-
clonal cases with stereotyped HCDR3 sequences showed
clearly less identical and/or conserved positions than those
found among multiclonal cases (underlined amino acids in
Tables 4B and 4C).
A. Henriques et al.
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Figure 1. Frequency of IGHV (A), IGHD (B), IGHJ (C) and both IGKV and IGLV (D) genes in multiclonal versus monoclonal CLL and non-CLL-like
B-cell clones. Diagrams show the relative frequency of each IG gene in multiclonal compared to monoclonal B-cell clones (black and white
bars, respectively). *Statistically significant differences were found between the multiclonal vs. monoclonal subgroups (P<0.05).
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Discussion
Multiclonal expansions of phenotypically aberrant B-cell
clones (MBLlo) have been reported as frequently present in
the general population35; of note, multiclonal expansions
of immunophenotypically normal B cells can also be
found in non-malignant diseases, such as autoimmune dis-
orders and inflammatory responses against several infec-
tious agents (e.g. Helicobacter pylori, hepatitis C virus).36,37
Whether clonal expansions of aberrant B cells found in
otherwise healthy individuals (MBLlo) reflect a prominent
reactive process against potent antigenic stimuli with
unknown clinical relevance, or whether they represent an
early (multi)clonal manifestation of a BCR-dependent neo-
plastic event, still remains to be established. In this regard,
it should be noted that between 30% and 40% of such
cases show cytogenetic changes shared by clinical MBL
and CLL, e.g. del(13q). Of note, among other large struc-
tural chromosomal alterations, clonal mosaicism involving
del(13q14) has also been recently found in peripheral
blood cell populations from otherwise healthy individuals,
particularly among subjects with more advanced age
(around 2-3% in the elderly), but its potential relationship
with MBL and CLL remains unknown.38,39 Compared to
the typical (monoclonal) MBL and B-CLPD, coexisting B-
cell clones from multiclonal MBL and B-CLPD may poten-
tially have a greater probability of interacting with com-
mon immunological determinants. However, there is still
little information about the potential existence of shared
BCR features in cases showing two or more coexisting B-
cell clones versus monoclonal cases. 
In the present study, we analyzed for the first time the
molecular and cytogenetic features of a large group (n=85)
of coexisting, but unrelated, B-cell clones from a series of
41 multiclonal MBL and B-CLPD cases, in comparison to
143 monoclonal cases. Overall, the former clones more
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Figure 2. Sequence distance cladogram of IGHV gene usage in CLL-like and non-CLL-like B-cell clones from multiclonal (dark colored bars in
the outside circle) and monoclonal (light colored bars in the outside circle) cases. Five major branches were found in the sequence distance
cladogram (i.e VH1, VH5, VH3, VH2-VH6, VH4). B-cell clones from individual multiclonal cases are represented by numbers; from them, those
phylogenetically closely related B-cell clones, which share the same IGHV family, are specifically identified by bold numbers in the inner part
of the circle and the symbol ¶. Of note, B-cell clones from multiclonal cases 14¶, 16¶ and 35¶ belong to closely located sub-branches of the
cladogram, with their IGHV sequences having amino acid identity of 79%, 76% and 69%, respectively. In turn, B-cell clones from the multi-
clonal case 32¶ belong to the VH4 major branch with IGHV sequences whose amino acid identity is 69%. Finally, the other B-cell clones from
multiclonal cases – cases 2¶, 11¶, 15¶, 18¶, 19¶, 27¶, 29¶, 31¶, 34¶, 37¶, 38¶ and 40¶– belong to the VH3 major branch, having IGHV
sequences with amino acid identity > 60% (68%, 73%, 73.4%, 61%, 79%, 70%, 63%, 77%, 69.9%, 70%, 72% and 68.4%, respectively). 
frequently showed cytogenetic and hematologic features
which are typical of the earliest MBL stages and/or initial
phases of CLL.18,36,37 Accordingly, B-cell clones from multi-
clonal cases more frequently corresponded to MBL cases,
whereas B-cell clones from monoclonal cases were more
frequently found to correspond to overt CLL. Of note,
these findings do not contradict the apparent discrepancy
between such associations and our previous observation
A. Henriques et al.
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Table 4. Multiclonal cases with coexisting B-cell clones sharing HCDR3 features (A). Multiclonal (B) and monoclonal (C) cases with B-cell clones show-
ing stereotyped HCDR3 amino acid sequences.
A. Multiclonal cases with coexisting B-cell clones showing HCDR3 regions of identical length or differing by one amino acid, and analogous composition of
amino acids in some parallel positions.
Multiclonal case ID VH families AA composition of HCDR3 (length) % homology#
8A V1-3 C_ARDRVVIIPDTTTINWFDP_W (19) 26
8B V3-53 C_ATHPTNIYTRWPYVSDMDV_W (19)
11A V3-23 C_ANRGETRGMDV_W (11) 54
11B V3-48 C_VRDGFHYYGFDI_W (11)
14A V4-34 C_ARGPDRLYSGSYTRFDY_W (17) 47
14B V4-34 C_ARREDDNFWSGFYMDV_W (16)
22A V3-74 C_ARDLDGSGSGVFDW_W (14) 64
22B V4-59 C_ARGWRSTDSYYGMDV_W (15)
29A V3-48 C_VRELWFGNGGDY_W (12) 42
29B V3-15 C_ATAGQGSADFLY_W (12)
31A V3-33 C_ARGELLHNWFDP_W (12) 58
31B V3-23 C_AKDGFPYYGFDI_W (12)
32A V4-39 C_ARQTGWLAPSDY_W (12) 54
32B V4-34 C_ARRDSSGWYYFDY_W (13)
33A V2-26 C_AGTNIPRQFDFWSGSSPNWFDP_W (22) 32
33B V3-53 C_ARAGGYCNSGSCRGAPRWYFDL_W (22)
Amino acids with analogous side-chain polarity (highlighted in italics): case 8 (I, V and F, M), case 11 (A, V and M, F), case 14 (L, F), case 22 (L, W; S, T and F, M), case 29 (A, V), case
31(L, F and H, Y), case 32 (T, S), case 33 (W, C) (EMBL-EBI Cambridge, UK). All cases had coexisting B-cell clones with CLL-like phenotype, except case 29 (one B-cell clone corre-
sponded to a MALT lymphoma-like phenotype), and cases 32 and 33 (both had one B-cell clone with a MZL-like phenotype). AA: amino acid; MALT: lymphoma of mucosa-associated
lymphoid tissue; MZL: marginal zone lymphoma. #Number of amino acids with analogous side-chain polarity (excluding the delineating C_ and _W positions)/HCDR3 length*100.
B. Multiclonal cases with B-cell clones showing stereotyped HCDR3 sequences.
Multiclonal cases ID V(D)J rearrangement AA composition of HCDR3
1 V3-30(D3-9)J6 C_AKYGGVKLRYFDWLLYGDYYYGMDV_W
2 V3-30(D3-9)J6 C_AKYGGVKLRYFDWLLYGDYYYGMDV_W
9 V3-23(D5-12)J6 C_ANRGETRGMDV_W
15 V3-23(D3-22)J6 C_ANRGESWGMDV_W
21 V3-21(D2-2)J6 C_ARDANGMDV_W
35 V3-21(D2-2)J6 C_ARDANGMDV_W
22 V3-74(D3-10)J4 C_ARDLDGSGSGVFDW_W
40 V3-21(D4-23)J4 C_ARDLDGGNSVFDC_W
Cases 1 and 2; 9 and 15; 21 and 35; 22 and 40 showed highly similar HCDR3 sequences; the underlined amino acids were different. All the listed B-cell clones had a CLL-like phe-
notype.
C. Monoclonal cases with B-cell clones showing stereotyped HCDR3 sequences.
Monoclonal Cases ID V(D)J rearrangement AA composition of HCDR3
117 V3-7(D3-3)J4 C_VRENELWSGGWGLDG_W
134 V3-7(D3-3)J4 C_VRENEFWSGGWGLDG_W
207 V4-39(D2-2)J6 C_ARHRLGYCSSTSCYYYYYGMDV_W
208 V4-39(D2-2)J6 C_ARHRLGYCSSTSCYYYYYGMDV_W
210 V4-39(D2-2)J6 C_ARDRLGYCSSTSCYYYYYGMDV_W
187 V4-b(-)J4 C_ARSWIQLWSEFDY_W
215 V4-b(D5-5)J4 C_ARAWIQLWSDFDY_W
180 V1-2/D6-19/J4 C_ARLQWLGISHFDY_W
204 V1-2/D6-19/J4 C_ARAQWLVLENFDY_W
196 V4-34/D3-16/J6 C_VRGYPSDYTERRYYYYGLDV_W
198 V4-34/D4-23/J6 C_ARGYGSTGETRRYYYYGMDV_W
Cases 117 and 134; 207, 208 and 210; 187 and 215; 180 and 204; 196 and 198 showed highly similar HCDR3 regions; the underlined amino acids (AA) were different. All the listed
B-cell clones had a CLL-like phenotype.
among CLL patients of a worse clinical outcome for mul-
ticlonal cases carrying non-CLL clones,11 as this latter
study was restricted to cases of overt CLL. In addition,
multiclonal cases were also associated with lower clonal
B-cell counts in peripheral blood, a lower number of cyto-
genetically altered clones, particularly of those carrying
del(13q), and a decreased frequency of clones with two or
more alterations. Of note, clonal expansions of non-CLL
like B-cell clones were also more frequently observed in
multiclonal than in monoclonal cases, such expansions
corresponding mainly to indolent lymphomas (e.g. mar-
ginal zone lymphoma) which have been associated with
chronic immune responses.40,41
Collectively, these results support the notion that the
presence of multiple B-cell clones in the same individual
more closely reflects the earlier stages of the disease. If
this holds true and chronic antigen stimulation is involved
in the onset of MBL and B-CLPD, as has recently been
suggested for MBL based on epidemiological studies,42 it
could be hypothesized that B-cell clones coexisting in
multiclonal cases would show more closely related BCR
features than B-cell clones from monoclonal cases. In this
regard, our results point out the existence of a slightly
higher level of HCDR3 homology among B-cell clones
from multiclonal versus monoclonal cases. In fact, in
around one fifth of all multiclonal cases, the coexisting B-
cell clones showed a high homology in their HCDR3
amino acid sequences; this also held true when we com-
pared the homology of the HCDR3 sequences of these
multiclonal cases against those of monoclonal cases
whose B-cell receptors were restricted to the same and/or
ontogenetically related IGHV families. In addition, the
frequency of stereotyped HCDR3 was also higher in mul-
ticlonal versus monoclonal cases. Such more closely relat-
ed BCR features would be found independently of
whether common antigens or superantigens are specifi-
cally involved, although the former would potentially
lead to a higher HCDR3 homology, whereas superanti-
gens could contribute to a greater frequency of usage of
specific IGHV, IGHD and/or IGHJ genes.13,43
In the present study, we found a similar frequency of
IGHV gene usage between coexisting multiclonal and
non-coexisting monoclonal B-cell clones in association
with a lower frequency of DH1, DH4 and DH7 as well as
JH6 families in multiclonal versus monoclonal B-cell
clones. Overall, these results suggest that no single anti-
gen or superantigen is involved in common in MBL and B-
CLPD. This is further supported by the relatively low per-
centage of alignment (≈50%) of the IGHV amino acid
sequences observed among the different clonal B-cell
populations analyzed, since such potential antigens -
including superantigens - would require interaction with
highly conserved sites at the IGHV/HCDR3 regions of the
BCR.44 Interestingly however, the higher representation of
DH1, DH4, DH7 and JH6 IGH gene segments in mono-
clonal versus multiclonal B-cell clones, together with the
slightly higher levels of HCDR3 homology observed
among coexisting (multiclonal) versus non-coexisting
(monoclonal) B-cell clones from MBL, CLL and other B-
CLPD cases, would indicate that still non-random selec-
tion of specific HCDR3, DH and JH segments could exist
in the MBL and CLL repertoire of both multiclonal and
monoclonal cases, which could reflect antigen-driven
selection and expansion of specific B-cell clones, at the
MBL and/or CLL stages.45
In this regard, based on the phylogenetic proximity of
their BCR, we could further identify, within the B-cell
clones from multiclonal cases, a considerably represented
subgroup of B-cell clones showing preferential usage of
IGHV3 genes and shorter HCDR3 sequences carrying a
significantly higher number of IGHVmutations versus the
unrelated clones. These results add support to the
involvement of a common antigen, at least in this specific
subset of cases.46 Interestingly, these “phylogenetically-
related” B-cell clones coexisting in multiclonal cases
showed a significantly higher frequency of del(13q) than
B-cell clones expressing other IGHV genes. These obser-
vations further suggest that the BCR features of this sub-
set of coexisting multiclonal B-cell clones could also con-
tribute to determining the probability and/or type of
cytogenetic progression occurring at the earliest stages of
the disease, as previously suggested by our group18 and
others.47,48 Further long-term, longitudinal studies are
required to confirm this hypothesis, since multiple pro-
ductive IGHV gene rearrangements may also underlie
clonal drift leading to selection for more aggressive clones
whose proportions would change over time.49
In summary, based on the molecular features of the
BCR and the cytogenetic profile of B-cell clones from the
multiclonal versus monoclonal cases of MBL, CLL and
other B-CLPD analyzed here, it may be concluded that
multiclonality is typically associated with early stages of
B-CLPD; at the same time it appears to reflect more close-
ly an antigen-driven nature of MBL and B-CLPD, with
potential involvement of multiple and diverse antigenic
determinants.
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